

09 Jun 2023 | Analysis

Chinese Language Podcast: ASCO

Junshi, BlissBio And Rising Chinese Oncology R&D

by **Brian Yang**

J&J and Legend's Carvykti shines at ASCO, while Junshi provides updates on anti-PD-1 antibody toripalimab. Alongside, ADCs from Biokin and BlissBio also step into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stood out in this special ASCO-focused episode of their latest Chinese-language podcast.

XXXXXXXXXXXXXXXXXXXX

XXXXXXXXScripXPinkSheetXXXXXXXXXXXXXASCOXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXDexterXXXXXXXXXXXXLeonXXXXXXXXXXXXASCOXXXXXXXXXXXX
2023XASCOXXXXXXXXXXXX

XXASCOXXADCXXCAR-TXXXXXXXX
XXASCOXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

LeonXXXX2023XASCOXXXXXXXXXXXXXXXXXXXXXXXXXXXXXASCOXXCAR-TXXXXXXXX
ADCXXXXXXXXXXXX

XXXXXXXX**Legend Biotech Corp.** XXX(**Johnson & Johnson**)XXXXXXXXXXXXXXXXBCMAXX
Carvykti(ciltacabtagene autoleucl)XXXXXXXXXXXXXXXXMSXXXXXXXXXXXXXXXXBCMAXXXXXXXX
XXXXXXXXXXXX

HER2 TIGIT ADC

Dexter ASCO NSCLC NSCLC Leon
([AstraZeneca PLC](#)) Tagrisso(osimertinib)

Dexter ([Shanghai Junshi Biosciences Co., Ltd.](#)) Tuoyi toripalimab
)

ADC Kelun Biotech) ([Merck & Co., Inc.](#)) [Eisai Co., Ltd.](#) [Bliss Biopharmaceutical \(Hangzhou\) Co., Ltd](#) Biokin

Leon
23% FDA BCMA
[BeiGene, Ltd.](#) BTK Brukinsa (zanubrutinib)

6 19 Citeline webinar ASCO

[Click here to explore this interactive content online](#) ✨